source
- Taiho and Cullinan's zipalertinib clears Phase 3 trial in EGFR-mutated lung cancerTaiho Oncology and Cullinan Therapeutics announced that their oral EGFR inhibitor zipalertinib successfully completed a registrational Phase 3 study in patients with a specific genetic form of lung…
- Former Legend Biotech chief Ying Huang named CEO of K2, targets $250 million Series A to license Asian assetsYing Huang spent the past seven years building one of the leading cancer cell‑therapy companies before stepping down as CEO of Legend Biotech. Weeks after announcing his departure, Huang has taken…